Page 46 - Aet News Today

FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.

Ketryx raised $14 million in Series A funds. The startups sells a platform — designed around FDA regulations and quality standards — that automates much of the work required from medical device companies’ development and quality teams.

Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way that sets it apart from the rest of its drug class.

A new partnership between Aledade and Anthem Blue Cross and Blue Shield in Virginia aims to improve access to value-based primary care for Medicaid members.

Rising out-of-pocket costs and barriers preventing or delaying the utilization of healthcare coverage highlight the need for a comprehensive approach that goes beyond insurance coverage alone and addresses the underlying issues affecting healthcare accessibility and affordability.

A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce.

As we embark on the winter season, the significance of respiratory health becomes even more pronounced. The challenges posed by cold weather, compounded by air pollution, necessitate a proactive approach.

Hims & Hers unveiled a new weight loss program on Monday that includes access to medications, educational content and digital tracking tools.

BIO’s new president and CEO is a familiar face. John Crowley, a longtime BIO board member, was named the life sciences industry trade group’s new leader, starting in March.

Regulators and experts consider patient-reported outcomes (PROs) as the gold standard when assessing a patient’s subjective treatment experience. As such, ePROs can be the key to product differentiation for sponsors seeking to highlight their product’s ease of administration, tolerability, or compatibility in combination with other components of a treatment regimen.